Michael Tanen

发表

Next Generation Ligand Binding Assays—Review of Emerging Real-Time Measurement Technologies

Stephanie Fraser, Mark Cameron, Edward O’Connor, 2014, The AAPS Journal.

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Michael Tanen, Matthew E. Kennedy, Wei Li, 2016, Science Translational Medicine.

Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK‐8931) in Healthy Japanese Adults: A Randomized, Placebo‐Controlled Study

Michael Tanen, M. Forman, M. Vugt, 2019, Clinical pharmacology and therapeutics.

P3-092: Prediction of short-term and long-term cognitive decline in moderate Alzheimer's disease patients in the Oxford project to investigate memory and aging (optima) cohort using CSF biomarkers

Daniel Holder, Michael Tanen, Abderrahim Oulhaj, 2008, Alzheimer's & Dementia.